Sunday, August 03, 2014 11:56:21 AM
Can tell all, even if they show and or announce efficacy, it is worthless. First, if it were strong and explosive enough, we would have heard about it. So they way the testing is set up, it may or may not work and proof is difficult to show. Nothing has came from this company since April. Who knows what they have or have not worked on.
They certainly did not deserve huge raises, extra shares, etc... based on performance, which is nothing ! Really, in 15 years, what have they done, license another persons cells and failed at trials with them..
Back to stroke, even if you hear efficacy... sell on the news and be thrilled to do it. Any efficacy would be based on spleen (not shrinking from the cells).. if that is the case, MSC's would work too and any of the 20 plus cell companies will beat ATHX to the market.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM